brain and spinal cord. 7 Contrary to other sedatives, dexmedetomidine does not cause respiratory depression. 7 Dexmedetomidine has been used as a sedative for various procedures, including cataract surgery. 8 -10 In addition, several studies have reported the efficacy and safety of dexmedetomidine for flexible bronchoscopy during awake fibreoptic intubation. 11 -14 However, no data are available comparing dexmedetomidine and sedation with remifentanil during flexible bronchoscopy for diagnostic and therapeutic procedures. We therefore conducted this prospective and randomized trial to compare dexmedetomidine and remifentanil administration during flexible fibreoptic bronchoscopy. We hypothesized that the use of dexmedetomidine would attenuate haemodynamic responses without respiratory depression during flexible bronchoscopy. Therefore, we compared remifentanil and dexmedetomidine during MAC for flexible bronchoscopy in terms of respiratory depression, haemodynamic stability, and patient and bronchoscopist satisfaction.
Methods

Patients
This randomized and double-blind study was registered with the Clinical Research information Service (CRiS), registration number KCT000064. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital and all patients provided written informed consent. A total of 72 subjects, aged 18-70 yr with ASA physical classification system status of I-III undergoing elective diagnostic flexible bronchoscopy from November 2010 to May 2011, were initially randomized to the two groups. Patients with baseline oxygen desaturation (resting hypoxaemia, ,90%), asthma or chronic obstructive pulmonary disease or a forced expiratory volume in 1 s (FEV 1 ) of ,1.0 litre, bradycardia [baseline heart rate (HR) ,60 beats min 21 ], hypotension [baseline systolic arterial pressure (SAP) ,100 mm Hg], in a pregnant state, and those intolerant or with an allergy to the study drug, and those unable or who refused to give informed consent were excluded (Fig. 1 ).
After premedication with i.v. midazolam 0.03 mg kg 21 in the reception area, subjects were transferred to the operating theatre. Subjects were monitored with ECG, pulse oximetry, and non-invasive arterial pressure during the procedure and recovery period [until post-anaesthesia care unit (PACU) discharge]. All subjects received supplemental oxygen (4 litre min 21 ) via a nasal cannula. Oxygen saturation, HR, and mean arterial pressure (MAP) were recorded at six time points (T0, baseline; T1, passage of the bronchoscope through vocal cords; T2, 1 min after T1; T3, 3 min after T1; T4, 5 min after T1; T5, 10 min after T1).
Flexible bronchoscopy
Topical anaesthesia was performed using 4% lidocaine spray in the oral cavity. A flexible bronchoscope (BF-1T60t, Olympus, Tokyo, Japan) was inserted transorally with subjects in the supine position. On visualizing the vocal cords and carina, 5 ml of 2% lidocaine was delivered through the bronchoscope channel for cough suppression. Additional topical anaesthesia was instilled at the discretion of the bronchoscopists. Subjects were randomly assigned to one of the two study groups: the propofol-remifentanil group (the PR group; n¼36) or the propofol -dexmedetomidine group (the PD group; n¼36). Bronchoscopists and subjects were unaware of group identities. Randomization to the two groups was performed using sealed envelopes by an anaesthesiologist not otherwise involved in the study. Study drugs were prepared by an anaesthetic nurse not involved in bronchoscopy; the syringe was labelled with the subject's inclusion number, and passed to another anaesthesiologist.
In both groups, bolus propofol (Anepol 
Outcome variables
The primary objectives were the incidences of oxygen desaturation and oxygen saturation trend between two groups. Oxygen desaturation was defined as an oxygen saturation of ,90% for more than 10 s. In the event of oxygen desaturation, oxygen delivery was increased from 4 to 10 litre min 21 , and then airway assistance manoeuvres (verbal and tactile stimulation, chin lift, jaw thrust, face mask, and manual ventilation) were performed in a stepwise manner and recorded. Secondary objectives were haemodynamic variables, cough scores, satisfaction scores of patients and bronchoscopists, requirements for oral cavity suction and instillation of topical anaesthesia, incidence of haemodynamic adverse events, level of sedation, and recovery time. Bronchoscopists (immediately after the procedure) and subjects (at least 6 h after the procedure to exclude the amnesic effect of midazolam) were questioned concerning the extent of coughing and level of satisfaction (recall, pain, and discomfort for patients and ease of the procedure), and to rate procedures using a numerical rating scale (NRS; 0, incessant coughing, a high level of discomfort; 100, no coughing, no discomfort). The willingness of subjects to undergo repeat bronchoscopy if needed was also recorded (as a 'yes' or 'no' response).
Levels of sedation were evaluated at the initiation of the procedure and 5 min after the procedure using the modified observer's assessment of alertness/sedation/(MOAA/S) scale (Appendix 1). 16 After the procedure, subjects were BJA Ryu et al.
transferred to the PACU and evaluated every 5 min using the modified post-anaesthesia discharge scoring (PADS) system until ready for discharge from the PACU (Appendix 2). 17 The criterion used for patient discharge was a PADS score of .9. Experiences of bronchoscopists, bronchoscope diameters, and procedure types were recorded. All doses of supplemental topical anaesthesia instillation and oral cavity suction requirements were judged by the bronchoscopists and recorded for each subject.
Adverse events
Bradycardia (a HR of ,60 beats min 21 or a decrease of 
Statistical analysis
In a preliminary study, the incidence of oxygen desaturation in the PR group was 40% and a reduction from 40% to 10% was considered to be of clinical importance (a¼0.05, power¼0.8). The analysis showed that 32 subjects per group would be sufficient to detect a difference between the two groups. Assuming a 10% dropout rate, the final sample size was set at 36 patients per group. Analysis was performed using SPSS version 15.0 for Windows (SPSS, Chicago, IL, USA). Student's t-test (two-sided) was used to compare group continuous variables, and repeatedmeasures analysis of variance (ANOVA) was used to analyse haemodynamic changes over time, using time as the between-subject factor. Intergroup differences at the different time points were analysed using the t-test. . Seventy-two subjects were randomized; two subjects (one from each group) were eliminated due to an unexpected delay in diagnosis and prolongation of operation time. PR group, propofol -remifentanil group; PD group: propofol-dexmedetomidine group. was used to analyse categorical variables. Data are presented as mean (SD) or as count (%). Two-sided P-values of ,0.05 were considered significant.
Results
Seventy-two subjects were randomized from November 2010 to May 2011 and two subjects (one from each group) were eliminated due to an unexpected delay in diagnosis and prolongation of operation time. Table 1 shows the patient and procedural characteristics. Table 2 shows the incidences of oxygen desaturation, steps of airway assistance, diameter of the bronchoscope in patients who encountered desaturation, and requirements for oral cavity suction. The incidence of oxygen desaturation was lower in the PD group (P¼0.01). In the PR group, one subject recovered from oxygen desaturation after verbal and tactile stimulation, two subjects by chin lift, and seven subjects after jaw thrust. One subject with oxygen desaturation in the PD group recovered after verbal and tactile stimulation. Need for oral cavity suction was less in the PD group (P¼0.03).
Oxygen saturation in the PR group was lower than in the PD group at T2 (1 min after passage of the bronchoscope through the vocal cords), but oxygen saturation during flexible bronchoscopy was not significantly different in the two groups (Fig. 2) .
No significant intergroup differences were observed in MAP or HR over time during the procedure (P¼0.5 for MAP, P¼0.09 for HR), but HR at T1 (time of scope passage through the vocal cords) was higher in the PR group (Fig. 3) .
More topical anaesthesia was required in the PD group than in the PR group (P,0.01, Table 3 ). Sedation level was comparable in the two groups at the initiation of the procedure, but there was a significant difference at 5 min after the procedure in the PACU (P,0.00, Table 3 ). Recovery time to reach a modified PADS of .9 in the PACU was greater in the PD group [18.4 (5.8) vs 7.6 (2.5) min] (P,0.001, Table 3 ).
Bronchoscopist NRS scores for coughing and satisfaction were significantly lower in the PD group (P,0.01), whereas the corresponding subject NRS scores and willingness to undergo repeat bronchoscopy were comparable in the two groups (Fig. 4, Table 4 ). *   T0  T1  T2   Time course   T3  T4  T5  T0  T1  T2 Time course T3 T4 T5
Fig 3
Changes in HR and MAP during flexible bronchoscopy. Repeated-measures ANOVA shows no significant difference in HR and MAP over time between the two groups, but HR at T1 (passage of the scope through the vocal cord) was higher in the PR group than in the PD group. Results are expressed as mean (SD). PR group, propofol -remifentanil group; PD group, propofol -dexmedetomidine group; T0, baseline; T1, passage of the bronchoscope through vocal cords; T2, 1 min after T1; T3, 3 min after T1; T4, 5 min after T1; T5, 10 min after T1. *P,0.05.
Haemodynamic and airway adverse events are summarized in Table 4 . Although the incidences of hypertension, hypotension, tachycardia, and arrhythmia were higher in the PR group, there were no significant differences. Four and three patients showed ventricular premature complex or atrial premature contractions, but all resolved spontaneously without haemodynamic instability.
Discussion
This randomized, double-blinded, comparative study was undertaken to compare dexmedetomidine and remifentanil in terms of respiratory depression, haemodynamic stability, tolerance of the procedure, recovery time, and adverse events. Our principal findings are that dexmedetomidine administration during flexible bronchoscopy can reduce the incidences of oxygen desaturation, airway secretion, and cough and bronchoscopist satisfaction scores compared with remifentanil infusion. Furthermore, dexmedetomidine was associated with a greater requirement for topical anaesthesia and a prolonged recovery time.
Previous studies have shown that dexmedetomidine provides proper sedation during awake fibreoptic intubation.
12 13 Bergese and colleagues 12 found that dexmedetomidine provided favourable patient and anaesthesiologist satisfaction responses and blunted haemodynamic responses to fibreoptic intubation. In another study, dexmedetomidine and midazolam were associated with better patient cooperation and higher patient satisfaction than midazolam alone. 13 However, a PubMed search failed to identify any previous comparative study on dexmedetomidine compared with another sedative regimen during flexible bronchoscopy for diagnostic and therapeutic procedures. The doses of remifentanil and dexmedetomidine in the current study were based on previous investigations. The maintenance dose range of remifentanil (0.02-0.08 mg indicates incessant cough and worst discomfort and 100 indicates no cough and no discomfort. The NRS by the bronchoscopist for cough and satisfaction was significantly lower in the PD group than in the PR group, whereas the cough and satisfaction NRS of the subjects were comparable between the two groups. Data are shown as mean (SD). *P,0.05. PR group, propofol -remifentanil group; PD group, propofoldexmedetomidine group. The major safety concerns with sedation during flexible bronchoscopy are apnoea and oxygen desaturation. 2 Several factors, such as airway secretions and reflex bronchoconstriction in response to insertion and bronchoscope manipulation, might be related to this sedation-related adverse event. 20 21 The incidence of oxygen desaturation in our remifentanil group was similar to those found in other studies on midazolam and opioids (21 -32%). 22 -24 In the present study, all subjects recovered from oxygen desaturation after a stepwise airway-assist manoeuvre (increase in oxygen flow, verbal and tactile stimulation, chin lift, and jaw thrust). Need for oral cavity suction was less in the dexmedetomidine group than in the remifentanil group, presumably due to the antisialagogue effect of dexmedetomidine. 25 In the present study, no anticholinergic agent was administered as a premedication or antisialagogue. Anticholinergic agents have been associated with haemodynamic disturbances such as tachycardia and hypertension. 22 In addition, previous studies have not demonstrated the beneficial effect of anticholinergic premedication on airway secretion, coughing, and patient discomfort during flexible bronchoscopy. 22 26 Haemodynamic variables, such as HR and MAP, over time and the incidences of haemodynamic adverse events were not different between the dexmedetomidine and remifentanil groups. However, the incidences of hypertension, hypotension, and tachycardia tended to be higher in the remifentanil group, although the differences did not reach statistical significance.
It was interesting that subjects rather than bronchoscopists in both groups reported high scores for coughing and satisfaction. This means that subjects in both groups were generally satisfied with the procedure without discomfort or coughing. The most likely explanations for this finding are the retrograde and anterograde amnesic effects of midazolam premedication and the sensation of well-being provided by propofol. 27 However, cough and satisfaction scores by bronchoscopists were significantly lower in the dexmedetomidine group than in the remifentanil group. Unlike remifentanil, dexmedetomidine has no antitussive effect and the passage of a flexible bronchoscope through the vocal cords might have led to coughing in the dexmedetomidine group. For this reason, topical anaesthesia with lidocaine was needed more frequently in the dexmedetomidine group.
Flexible bronchoscopy is usually performed as an ambulatory procedure. In the present study, mean recovery time was greater in the dexmedetomidine group [18.4 (5.8) vs 7.6 (2.5) min], although respiratory depression in the PACU was not observed in either group.
The current study has a number of limitations that should be considered. First, patients with an FEV 1 of ,1 litre were excluded. Jones and O'Driscoll 28 found that the majority of patients with an FEV 1 of .1 litre do not show oxygen desaturation or require routine oxygen supplementation during flexible bronchoscopy. Accordingly, the exclusion of patients with an FEV 1 of ,1 litre might have reduced the observed incidence of oxygen desaturation. On the other hand, the definition of oxygen desaturation (,90% for more than 10 s) applied was stricter than those of previous studies (,90% for .30 s or 1 min). 24 29 -31 Secondly, several bronchoscopists performed the flexible bronchoscopy, which might have influenced our results. However, levels of experience and procedural times were not significantly different in our two study groups. In summary, dexmedetomidine was associated with lower incidences of oxygen desaturation and reduced need for oral cavity suction than remifentanil during MAC for flexible bronchoscopy. However, dexmedetomidine seemed to be less effective (lower cough and bronchoscopist satisfaction scores and a more frequent need for topical anaesthesia) than remifentanil.
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